-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| Alzheimer's vaccine shows good momentum |
In the future, the name of Alzheimer's disease (AD) may appear in the long list of vaccines
.
The results of a phase 2 clinical trial showed that the AD vaccine named AADvac1 is safe and can induce an immune response in patients with mild AD
The toxic form of tau protein will accumulate and spread in the brain of AD patients, which is also a pathological feature of the disease
.
This protein is thought to cause a large number of neuronal deaths and eventually cause dementia
An international collaborative team conducted a randomized placebo-controlled trial involving 196 patients with mild AD (mean age 71.
4 years, 45.
1% male, 100% white)
.
Researchers injected these patients with multiple doses of AADvac1 polypeptide vaccine or placebo, and monitored the safety, immunogenicity (that is, the ability of the vaccine to induce an immune response) and clinical efficacy of the vaccine over two years
The researchers found that the vaccine is safe as a whole, and the vaccination group can produce a large number of antibodies to the peptides of the vaccine
.
However, this vaccine did not have a statistically significant positive or negative effect on the cognitive function of the entire study sample
The researchers said that although patients tolerate AADvac1 well and can produce an immune response to tau protein, the vaccine cannot produce statistically significant cognitive benefits.
This may be because some patients lack the pathological manifestations of tau protein.
Or because the sample size of the study is small
.
Therefore, a larger-scale stratified trial based on the existence of disease biomarkers is still needed to repeat the above research results and fully evaluate the possible clinical efficacy of AADvac1
Related paper information: https://doi.
https://doi.
org/10.
1038/s43587-021-00070-2 https://doi.
org/10.
1038/s43587-021-00070-2
